Perspectives
Nature Reviews Neuroscience 9, 638-646 (August 2008) | doi:10.1038/nrn2453
Opinion: How can we realize the promise of personalized antidepressant medicines?
Florian Holsboer1 About the author
Abstract
Personalized medication that is based on pharmacogenetic data has long been expected to improve the efficacy of treatments for neurological and psychiatric disorders, including depression. However, the complexity of the regulation of gene transcription and its interactions with environmental factors means that straightforward translation of individual genetic information into tailored treatment is unlikely. Nevertheless, when data from genomics, proteomics, metabolomics, neuroimaging and neuroendocrinology are used in combination, they could lead to the development of effective personalized antidepressant treatment that is based on both genotypes and biomarkers. This process will require many further steps and collaboration between basic and clinical neuroscience.
Author affiliations
-
Florian Holsboer is at the Max Planck Institute of Psychiatry, Kraepelinstrasse 2–10, 80804 Munich, Germany.
Email: holsboer@mpipsykl.mpg.de
Published online 16 July 2008
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Temporal changes in allele frequency, genetic variation and inbreeding depression in small populations of the guppy, Poecilia reticulataHeredity Original Article
Family-based association of FKBP5 in bipolar disorderMolecular Psychiatry Original Article
Pharmacological and Nonpharmacological Factors Influencing Hypothalamic?Pituitary?Adrenocortical Axis Reactivity in Acutely Depressed Psychiatric In-patients, Measured by the Dex-CRH TestNeuropsychopharmacology Original Article
See all 31 matches for Research
